Weill Cornell Medicine
Welcome,         Profile    Billing    Logout  
 4 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fishman, David A
NCT05562778: Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment

Recruiting
N/A
150
US
Chatbot
Weill Medical College of Cornell University
Gynecologic Cancer, Hereditary Cancer Syndrome
12/25
12/25
Yan, Xiaojian
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT05737303: Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Recruiting
3
538
RoW
nab-paclitaxel combined with carboplatin, paclitaxel combined with carboplatin
Women's Hospital School Of Medicine Zhejiang University, Jiaxing Maternity and Child Health Care Hospital, Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Sun Yat-sen University, Qilu Hospital of Shandong University, Ningbo No. 1 Hospital, Ningbo Women & Children's Hospital, Sir Run Run Shaw Hospital
Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV
12/24
12/27
Yuan, Jianlin
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting
2
196
RoW
TQB2450, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer
12/21
04/22
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Recruiting
2
460
RoW
HS-20089
Hansoh BioMedical R&D Company
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
12/25
12/27
NCT05856929: Sexual Dysfunction After Renal Transplantation

Recruiting
N/A
500
RoW
no Intervention
Xijing Hospital
Sexual Dysfunction
01/24
06/24
NCT06677814: Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients

Recruiting
N/A
700
RoW
Xijing Hospital
Premature Ejaculation, Anxiety
03/25
05/26
Zhang, Huifeng
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
NCT04152967: New Designed ePTFE Valved Conduits for Surgical Reconstruction of Right-ventricular Outflow Tract

Recruiting
N/A
200
RoW
new-designed PTFE valved conduits, Bovine jugular vein valved conduits
Children's Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai Children's Medical Center
Right Ventricular Outflow Tract Absent, Congenital Heart Disease, Pulmonary Valve Disorders
12/21
11/22
Flores, Lina
NCT04886986: Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Suspended
1/2
48
US
225Ac-J591, 177Lu-PSMA-I&T, 177Lu-PNT2002, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC
Weill Medical College of Cornell University, POINT Biopharma
Prostate Cancer
12/25
12/27
NCT04506567: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Suspended
1/2
105
US
225Ac-J591, 68Ga-PSMA-HBED-CC injection, 68Ga-PSMA-11
Weill Medical College of Cornell University
Prostate Cancer
06/25
06/27
Zhao, Hongwei
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/24
12/24

Download Options